Figures & data
Table 1. Summary of included studies.
Figure 1. Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) flow diagram for new systematic reviews which included searches of databases, registers and other sources. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. From Page et al. [16]. For more information, see http://www.prisma-statement.org/
![Figure 1. Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) flow diagram for new systematic reviews which included searches of databases, registers and other sources. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. From Page et al. [16]. For more information, see http://www.prisma-statement.org/](/cms/asset/c4f21f40-6508-47ba-bf15-00b802585790/icmt_a_2273524_f0001_c.jpg)
Figure 2. Forest plots of primary outcomes: menopausal hormone therapy (MHT) versus controls on (a) non-fatal myocardial infarction, (b) cardiovascular disease (CVD) death and (c) stroke. CI, confidence interval; M-H, Mantel–Haenszel.
![Figure 2. Forest plots of primary outcomes: menopausal hormone therapy (MHT) versus controls on (a) non-fatal myocardial infarction, (b) cardiovascular disease (CVD) death and (c) stroke. CI, confidence interval; M-H, Mantel–Haenszel.](/cms/asset/5975c816-bf96-404e-99a6-44591ecf16b6/icmt_a_2273524_f0002_c.jpg)
Figure 3. Clinical approach to the management of menopausal symptoms in women with cardiovascular disease (CVD). †Diabetes mellitus may be associated with increased progression of atherosclerosis. *Oral menopausal hormone therapy (MHT) is associated with increased blood pressure and increased thrombotic risk.
![Figure 3. Clinical approach to the management of menopausal symptoms in women with cardiovascular disease (CVD). †Diabetes mellitus may be associated with increased progression of atherosclerosis. *Oral menopausal hormone therapy (MHT) is associated with increased blood pressure and increased thrombotic risk.](/cms/asset/5712ad6a-f844-4f1b-9c1e-d3b76529bcb4/icmt_a_2273524_f0003_c.jpg)
Supplemental Material
Download MS Word (14.8 KB)Supplemental Material
Download MS Word (33.5 KB)Supplemental Material
Download MS Word (13.5 KB)Supplemental Material
Download MS Word (17 KB)Supplemental Material
Download MS Word (248.9 KB)Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.